PVCT

PROVECTUS BIOPHARMACEUTICALS, INC. (DE)

PVCT

Overview Fund Activity

Delisted

PVCT was delisted on the 13th of October, 2016.

Back to rankings

Financial journalist opinion

Provectus Biopharmaceuticals Announces Publication of Moffitt Cancer Center Research on PV-10 for Head and Neck Cancer

KNOXVILLE, Tenn., June 26, 2025 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced the publication of preclinical research by Christine Chung, MD and her team (the “Chung Lab”) at Moffitt Cancer Center in Tampa, Florida (“Moffitt”), evaluating intratumoral PV-10 in models of head and neck squamous cell carcinoma (“HNSCC”).

Provectus Biopharmaceuticals Announces Publication of Moffitt Cancer Center Research on PV-10 for Head and Neck Cancer

Provectus Biopharmaceuticals Announces Investor Webinar for 2025 Annual Meeting of Stockholders

KNOXVILLE, Tenn., June 09, 2025 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) announced today that its 2025 annual stockholder meeting (the “Annual Meeting”), including shareholder meeting activities and a company update, will also be accessible by Zoom Webinar.

Provectus Biopharmaceuticals Announces Investor Webinar for 2025 Annual Meeting of Stockholders

Provectus Biopharmaceuticals Announces Seed Financing for VisiRose, Provectus's Spinoff Company for Rose Bengal-Based Eye Drugs

KNOXVILLE, Tenn., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced a $3 million seed financing round for VisiRose, Inc. (“VisiRose”), Provectus's Founded Entity that is developing novel ocular therapeutics.

Provectus Biopharmaceuticals Announces Seed Financing for VisiRose, Provectus's Spinoff Company for Rose Bengal-Based Eye Drugs

Provectus Biopharmaceuticals, Inc. (PVCT) Q4 2024 Earnings Call Transcript

Provectus Biopharmaceuticals, Inc. (OTC:PVCT) Q4 2024 Results Conference Call November 14, 2024 2:00 PM ET Company Participants Alyssa Barry - Co-Founder & Principal of Investor Relations, Alliance Advisors IR Ed Pershing - Chairman Dominic Rodrigues - Board Vice Chairman Alyssa Barry Good afternoon, good morning, good evening, depending on where you are. Welcome to Provectus Biopharmaceuticals Fourth Quarter Investor Update.

Provectus Biopharmaceuticals, Inc. (PVCT) Q4 2024 Earnings Call Transcript

Provectus Biopharmaceuticals Announces Fourth Quarter 2024 Conference Call

KNOXVILLE, Tenn., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) announced today that it will host a conference call on Thursday, November 14, 2024 starting at 2 p.m. EST to provide Company updates.

Provectus Biopharmaceuticals Announces Fourth Quarter 2024 Conference Call

Provectus Biopharmaceuticals Announces Notices of Allowance and Award for U.S. Patents of Rose Bengal Sodium in Virology, Pediatric Solid Tumor Cancers, and Vaccines

KNOXVILLE, TN, March 12, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that the United States Patent and Trademark Office (“USPTO”) has allowed patent application 17/212,723, titled “Novel Uses of Halogenated Xanthenes in Oncology and Virology.” The application covers the use of Provectus's pharmaceutical-grade rose bengal sodium (“RBS”) drug substance for the treatment of infectious diseases, such as coronaviruses.

Provectus Biopharmaceuticals Announces Notices of Allowance and Award for U.S. Patents of Rose Bengal Sodium in Virology, Pediatric Solid Tumor Cancers, and Vaccines

Provectus Biopharmaceuticals Announces Acceptance of Cancer Immunotherapy PV-10 Abstract for HNSCC at AACR 2024 Annual Meeting

KNOXVILLE, TN, March 07, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that data from preclinical research on PV-10 (rose bengal sodium) for the treatments of human papillomavirus (“HPV”)-positive and HPV-negative head and neck squamous cell carcinoma (“HNSCC”) will be presented at the upcoming annual meeting of the American Association for Cancer Research (“AACR”), to be held April 5-10, 2024 in San Diego, California.

Provectus Biopharmaceuticals Announces Acceptance of Cancer Immunotherapy PV-10 Abstract for HNSCC at AACR 2024 Annual Meeting

Provectus Biopharmaceuticals Announces Acceptance of Pharmaceutical-Grade Rose Bengal Sodium Abstract for Poster Presentation at 2024 Society for Investigative Dermatology (SID) Annual Meeting

KNOXVILLE, TN, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that data from ongoing preclinical research on the topical administration of a formulation of Provectus's proprietary, pharmaceutical-grade, small molecule, rose bengal sodium (“RBS”) drug substance are being presented at the annual meeting of the Society for Investigative Dermatology (“SID”), to be held May 15-18, 2024 in Dallas, Texas.

Provectus Biopharmaceuticals Announces Acceptance of Pharmaceutical-Grade Rose Bengal Sodium Abstract for Poster Presentation at 2024 Society for Investigative Dermatology (SID) Annual Meeting

Provectus Biopharmaceuticals, Inc. (PVCT) Q1 2024 Earnings Call Transcript

Provectus Biopharmaceuticals, Inc. (PVCT) Q1 2024 Earnings Call Transcript

Provectus Biopharmaceuticals Announces First Quarter 2024 Conference Call

KNOXVILLE, TN, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that it will host a conference call starting at 3 p.m. EST on Thursday, February 22, 2024, to provide Company updates.

Provectus Biopharmaceuticals Announces First Quarter 2024 Conference Call

See News Rankings

Charts implemented using Lightweight Charts™